患有多发性骨髓瘤的患者因抗凝血剂血栓预防而出现出血风险:MarketScan分析
Diego Adrianzen-Herrera1, Katherine Giorgio2, Rob F Walker2
1Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA.
Research and practice in thrombosis and haemostasis
|May 27, 2024
概括
多发性骨髓瘤 (MM) 患者的血栓预防显示出严重出血的风险较低. 抗凝剂治疗没有增加出血事件,但年龄和并发症是显著的危险因素.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 多发性骨髓瘤 (MM) 患者面临高风险的静脉血栓塞栓症 (VTE).
- 建议使用抗凝血剂预防,但由于对出血风险的担忧,使用率不足.
- 有限的数据存在于MM中与血栓预防相关的严重出血率.
研究的目的:
- 确定多发性骨髓瘤患者接受血栓预防治疗的严重,住院出血的发生率.
- 在这个患者群体中确定与出血相关的临床风险因素.
主要方法:
- 来自MarketScan数据库 (2013-2021) 的6656名多发性骨髓瘤患者的分析.
- 通过处方声明识别的血栓预防;使用坎宁汉算法评估住院出血.
- 考克斯回归模型被用来识别出血风险因素.
主要成果:
- 只有6.6%的MM患者接受了抗凝血剂血栓预防药.
- 在接受预防的患者 (每1000人年7.8) 和未接受预防的患者 (每1000人年10.1) 之间,严重出血的发生率相似.
- 血栓预防没有增加出血风险;年龄,并发症指数,出血史,高血压和病是显著的风险因素.
结论:
- 在多发性骨髓瘤患者中,从血栓预防中发生严重出血的风险很低.
- 同时使用抗凝剂治疗并没有提高该队列的出血风险.
- 识别临床风险因素,如年龄和并发症,对于管理MM患者出血风险至关重要.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
681
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
681
01:24Disorders of Hemostasis
845
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
845
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
521
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521